COPD and Intestinal Dysbiosis

R.S. Bayramova*, M.S. Novruzova, H.M. Aliyeva and J.X. Talibova

Azerbaijan Medical University, Department of Medical Microbiology and Immunology, Azerbaijan
*Corresponding author

ABSTRACT

By WHO forecasts, a further increase in the prevalence and mortality of COPD among people of working age is predicted, due to uncontrolled environmental pollution, a tobacco pandemic, an increase in the level of allergens and a genetic predisposition. In chronization and progression of COPD, there is a violation of cellular and humoral immunity, production of pro-inflammatory cytokines of phagocytic cell activity that contribute to the persistence of the inflammatory process in the lungs. Therefore, the study of the state of intestinal microflora in patients with COPD and the timely correction of impaired microbiocinosis is an important task that needs to be studied. Patients with COPD have a chronic inflammatory process in the bronchopulmonary system, accompanied by inhibition of the functional activity of neutrophils, which complicates the formation of humoral immunity and leads to a persistent course of the disease with frequent exacerbations. The revealed violations of COPD associated with intestinal dysbacteriosis indicate pronounced manifestations of secondary immunodeficiency. The obtained data allow us to recommend bacteriological and immunological examination of patients with COPD to identify immunological deficiencies with concomitant intestinal dysbiosis for the purpose of complex treatment with the use of immunocorrecting and probiotics.

Keywords: Chronic obstructive pulmonary, Secondary immunodeficiency, Inflammatory process, Chronization, Phagocytosis activity, Normal intestinal microflora, Dysbiotic changes, Bifidus bacteria and lactobacilli, E.coli

Article Info
Accepted: 20 June 2019
Available Online: 10 July 2019

Introduction

Today, chronic obstructive pulmonary disease (COPD) is the most common disease of the bronchopulmonary system, leading to a decrease in the quality of life of patients and is characterized by frequent infectious-related exacerbations. Every new exacerbation not only increases the risk of reducing respiratory function, but also causes a higher incidence of antibiotic therapy (1, 2)

By WHO forecasts, a further increase in the prevalence and mortality of COPD among people of working age is predicted, due to uncontrolled environmental pollution, a tobacco pandemic, an increase in the level of allergens and a genetic predisposition (3, 4, 5, 6). In terms of environmental and social disadvantage in patients with COPD, the immune system is inhibited, leading to the formation of secondary immunodeficiency and transformation of acute respiratory system diseases into a protracted chronic form (7.8)

When chronization and progression of COPD, there is a violation of cellular and humoral immunity, production of pro-inflammatory...
cytokines of phagocytic cell activity that contribute to the persistence of the inflammatory process in the lungs (9, 10, 11, 12, 13).

It has been established that bronchial tree infections are the leading cause of COPD exacerbation. Bacterial pathogens in significant quantities are detected in 50-70% of patients with exacerbation of the disease. The role of gram-negative microflora (Hemophilus influenza, Moraxella catarralis) increases in people with severe COPD (14, 15, 16, 17). In the period of infectious exacerbation of COPD, the intensification of the inflammatory process, leading to deterioration in the ventilation function of the lungs, lengthens the recovery process. As COPD progresses, exacerbations become frequent (18).

Conducted etiotropic therapy aimed at eliminating the infectious process increases the incidence of adverse reactions from the gastrointestinal tract (diarrhea, colitis, excessive bacterial growth syndrome), the widespread use of antibacterial drugs reduces the duration of exacerbations, but causes intestinal dysbiosis and antibiotic resistance.

It is proved that the normal intestinal microflora of a healthy person protects against colonization by pathogenic microorganisms and participates in the implementation of immunological defense mechanisms. When the species and quantitative composition of the intestinal microflora, developing as a result of the underlying disease or on the background of antibacterial therapy, change not only the digestive processes, but also the immune mechanisms that lead to local and systemic disorders in the internal environment of the microorganism through the release of proinflammatory and anti-inflammatory cytokines, regulatory peptides regeneration and apoptosis (8, 19, 20, 21).

Therefore, the study of the state of intestinal microflora in patients with COPD and the timely correction of impaired microbiocinosis is an important task that needs to be studied.

**Materials and Methods**

Surveyed 20 people, of whom 11 (n = 11) patients with moderate COPD who were treated in the pulmonary department, 9 people - almost healthy individuals made up the control group (n = 9). The average age of the subjects was 56 ± 5.4 years. The observed patients received antibiotic therapy in the last year. The diagnosis of COPD was made by clinicians on the basis of clinical and instrumental methods of examination. All patients underwent feces for dysbacteriosis, taking into account the number of *Bifidobacteria, Lactobacilli, E.coli* with normal enzymatic activity and hemolyzing Escherichia coli, as well as other conditional pathogenic microorganisms (UPM).

In patients with COPD, the intensity of inflammation of the bronchial mucosa was assessed. Phagocytic activity of neutrophils (PAN), phagocytic number (PN), and the intensity of neutrophil oxygen-dependent metabolism in the spontaneous and induced nitro-tetrazolium recovery (NBT) test were determined.

The results were processed using the Statistic 6.0 program. The significance of differences in the comparative parameters was determined by the criterion of the Student. To determine the relationship between the individual indicators used the correlation analysis according to Pearson.

**Results and Discussion**

On the basis of anamnestic data, in most patients with COPD, in addition to respiratory symptoms, there were complaints from the
gastrointestinal tract: nausea, belching, and stool dysfunction or diarrhea. Dysbiotic changing was assessed by N. M. Grachova’s classification (22).

I degree of dysbacteriosis was characterized by a decrease in the total number of the main representatives of microflora (bifido bacteria and lactobacilli to $10^7$ CFU / g), a decrease in the number of intestinal basils with normal fermentation activity to $10^6$ CFU / g.

The II degree of intestinal dysbacteriosis was manifested by a decrease in the level of microflora (bifidus bacteria and lactobacilli to $10^5$ CFU / g), an increase in lactose-negative E. coli and an increase in the level of conditionally pathogenic enterobacteria.

The III degree of dysbacteriosis is expressed by a strong decrease in the total amount of intestinal microflora ($Bifidobacteria$ and $Lactobacilli$ to 103 CFU / g), the absence of $Escherichia$ with normal enzymatic activity, an increase in the level of conditionally pathogenic enterobacteria, $Staphylococcus aureus$, of the Candida genus 105 CFU / g.

The III degree of dysbacteriosis is expressed by a strong decrease in the total amount of intestinal microflora ($Bifidobacteria$ and $Lactobacilli$ to 103 CFU / g), the absence of $Escherichia$ with normal enzymatic activity, an increase in the level of conditionally pathogenic enterobacteria, $Staphylococcus aureus$, of the Candida genus 105 CFU / g.

The II degree of intestinal dysbacteriosis was manifested by a decrease in the level of microflora (bifidus bacteria and lactobacilli to $10^5$ CFU / g), an increase in lactose-negative E. coli and an increase in the level of conditionally pathogenic enterobacteria.

The III degree of dysbacteriosis was expressed by a strong decrease in the total amount of intestinal microflora ($Bifidobacteria$ and $Lactobacilli$ to 103 CFU / g), the absence of $Escherichia$ with normal enzymatic activity, an increase in the level of conditionally pathogenic enterobacteria, $Staphylococcus aureus$, of the Candida genus 105 CFU / g.

The studied indicators of the state of the immune status in patients with COPD investigated the functional activity of neutrophils in patients with COPD: phagocytic number (PP), phagocytic index (PI) and NBT.

The study of neutrophil phagocytic index in the group of patients with COPD (n = 11) showed that the PI was 67.1 ± 2.37%, the PP - 2.1 ± 0.08 cells.

In the study of the function of phagocytosis in the group of patients with COPD (n = 11), there was a clear tendency to decrease in PI - 52.1 ± 1.15%. Apparently, in patients with COPD, opsonizes are depleted, in particular, the C3 component of complement and IgG (23).

In the study of PP in patients with COPD, the values were higher than the control group (2.1 ± 0.08) and amounted to 2.5 ± 0.11, which could be associated with the most pronounced activation of neutrophils in these patients.

The study of NBT-test (neutrophil phagocytic activity) showed that in patients with COPD there was an increase in both spontaneous and induced NBT-test compared with the control group. If in the group of healthy individuals (n = 9) the mean values of the spontaneous NBT test were 9.2 ± 2.31 units, the induced NBT test was 14.5 ± 2.14 units, then among patients with COPD the values were 15.1 ± 1.08 U and 19.2 ± 3.14 U accordingly.

Thus, patients with COPD have a chronic inflammatory process in the bronchopulmonary system, accompanied by inhibition of the functional activity of neutrophils, which complicates the formation of humoral immunity and leads to a persistent course of the disease with frequent exacerbations.

The revealed violations of COPD associated with intestinal dysbacteriosis indicate pronounced manifestations of secondary immunodeficiency.

The obtained data allow us to recommend bacteriological and immunological examination of patients with COPD to
identify immunological deficiencies with concomitant intestinal dysbiosis for the purpose of complex treatment with the use of immunocorrecting and probiotics.

References

1. Global Initiative for Chronic Obstructive Lung Disease URL. GOLD Repost 2011 Feb. 21;
2. Avdeev SN. Antibacterial therapy for exacerbation of COPD. Pulmonology. 2010. №2 from 96-107


How to cite this article: